TP53 and cancer: Gene correction might nonetheless be beneficial if FANC-/TP53- double mutants are more likely to progress to cancer than FANC+/TP53- mutants, but it is unlikely to lower the overall TP53- burden if TP53 mutation rates and proliferative advantages are comparable between corrected and uncorrected tissue.